BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment . BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.
